



## Company Overview

Neuralstem is a biopharmaceutical company developing novel treatments for nervous system diseases of high unmet medical need. Our lead asset, NSI-189, is a new chemical entity in Phase 2 clinical development for major depressive disorder (MDD). Our transplantational stem cell asset, NSI-566, is a spinal cord-derived neural stem cell line being tested in stroke, chronic spinal cord injury (cSCI) and Amyotrophic Lateral Sclerosis (ALS). These product candidates are based on the company's proprietary neural stem cell technology.

## Neuralstem Announces Publication of Long-Term Follow-up Data on ALS in the Annals of Clinical and Translational Neurology

May 3 2018, 7:00 AM EDT

## Neuralstem to Present Clinical Update at the Alliance for Regenerative Medicine 6th Annual Cell & Gene Therapy Investor Day

Apr 11 2018, 7:00 AM EDT

## Neuralstem Announces First Surgery Completed in Cervical Cohort of Phase 1 Clinical Trial in Patients with Chronic Spinal Cord Injury

Apr 10 2018, 7:00 AM EDT

## Stock Overview

Symbol	CUR
Exchange	NASDAQ
Shares OS	15,160,014
Market Cap	\$25.77M
Last Price	\$1.70
52-Week	\$0.88 - \$6.60

05/09/2018 04:00 PM EDT

## Investor Relations

Argot Partners  
 Kimberly Minarovich  
 T: 212-600-1902  
[kimberly@argotpartners.com](mailto:kimberly@argotpartners.com)

## Management Team

**Richard Daly**  
CEO

**Karl Johe, Ph.D.**  
CSO

**David Recker**  
CMO

**Thomas Hazel, Ph.D.**  
Senior Vice President, Research

## Neuralstem, Inc.

20271 Goldenrod Lane  
Suite 2024  
Germantown, MD 20876

## Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.